Regeneron Pharmaceuticals Inc (REGN)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Regeneron Pharmaceuticals Inc (REGN)
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Key Insights
Critical company metrics and information
Share Price
$765.31Market Cap
$84.10 BillionTotal Outstanding Shares
108.07 Million SharesTotal Employees
14,176Dividend
No dividendIPO Date
April 2, 1991SIC Description
Pharmaceutical PreparationsHomepage
https://www.regeneron.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $-1.51 Billion |
| Net Cash Flow | $-148.40 Million |
| Net Cash Flow From Operating Activities | $4.25 Billion |
| Net Cash Flow From Investing Activities | $-2.88 Billion |
| Net Cash Flow From Financing Activities, Continuing | $-1.51 Billion |
| Net Cash Flow From Operating Activities, Continuing | $4.25 Billion |
| Net Cash Flow, Continuing | $-148.60 Million |
| Exchange Gains/Losses | $200,000.00 |
| Net Cash Flow From Investing Activities, Continuing | $-2.88 Billion |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Basic Average Shares | $323.90 Million |
| Diluted Earnings Per Share | $40.42 |
| Income/Loss From Continuing Operations Before Tax | $4.97 Billion |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Nonoperating Income/Loss | $996.00 Million |
| Net Income/Loss Attributable To Parent | $4.65 Billion |
| Benefits Costs and Expenses | $8.88 Billion |
| Diluted Average Shares | $346.70 Million |
| Basic Earnings Per Share | $43.24 |
| Net Income/Loss Available To Common Stockholders, Basic | $4.65 Billion |
| Costs And Expenses | $9.87 Billion |
| Research and Development | $4.90 Billion |
| Selling, General, and Administrative Expenses | $2.90 Billion |
| Income/Loss From Continuing Operations After Tax | $4.65 Billion |
| Revenues | $13.85 Billion |
| Operating Income/Loss | $3.97 Billion |
| Operating Expenses | $9.87 Billion |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Income Tax Expense/Benefit | $314.90 Million |
| Net Income/Loss | $4.65 Billion |
| Other Operating Expenses | $2.08 Billion |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Noncurrent Liabilities | $4.46 Billion |
| Equity Attributable To Parent | $29.33 Billion |
| Liabilities And Equity | $37.44 Billion |
| Equity | $29.33 Billion |
| Other Non-current Assets | $16.99 Billion |
| Other Current Assets | $16.32 Billion |
| Inventory | $3.02 Billion |
| Current Assets | $19.33 Billion |
| Current Liabilities | $3.66 Billion |
| Noncurrent Assets | $18.11 Billion |
| Other Current Liabilities | $3.16 Billion |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Accounts Payable | $497.30 Million |
| Liabilities | $8.12 Billion |
| Assets | $37.44 Billion |
| Intangible Assets | $1.12 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Related Companies
View additional S&P 500 companies similar to Regeneron Pharmaceuticals Inc (REGN)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.